Controversy Over Haffkine's Legacy: The DPT Vaccine Seed Strain Debate

Jayant Patil opposes Maharashtra's plan to sell DPT vaccine seed strain to a private firm, highlighting Haffkine Bio-Pharmaceutical's ability to produce affordable vaccines. He urges the cancellation of the sale, which threatens Haffkine's legacy, and reinforces concerns over commercial interests in a public health matter.

NCP leader Jayant Patil has raised objections against Maharashtra's plans to sell the DPT vaccine seed strain to a private entity.

Patil argues that state-run Haffkine Bio-Pharmaceutical Corporation could offer these vaccines affordably, thus preserving the legacy of bacteriologist Waldemar Haffkine.

The proposed sale to Reliance Life Sciences raises concerns over privatization of a public health asset, valued in the billions, drawing criticism from other political figures.

(With inputs from agencies.)